The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Aug. 06, 2024
Filed:
Jul. 06, 2022
Applicant:
Regeneron Pharmaceuticals, Inc., Tarrytown, NY (US);
Inventors:
Andrew Tustian, Millwood, NY (US);
Ankit Vartak, Greenwich, CT (US);
Thomas Daly, New City, NY (US);
Erica Pyles, New City, NY (US);
Nisha Palackal, White Plains, NY (US);
Shunhai Wang, Scarsdlae, NY (US);
Ning Li, New Canaan, CT (US);
Assignee:
Regeneron Pharmaceuticals, Inc., Tarrytown, NY (US);
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07K 1/36 (2006.01); A61K 38/18 (2006.01); C07K 1/113 (2006.01); C07K 1/16 (2006.01); C07K 1/18 (2006.01); C07K 1/22 (2006.01); C07K 14/71 (2006.01); C07K 16/22 (2006.01); C07K 16/28 (2006.01); C12N 5/00 (2006.01); C12N 15/66 (2006.01); C12P 21/02 (2006.01); C12P 21/06 (2006.01); G01N 30/80 (2006.01); G01N 30/02 (2006.01);
U.S. Cl.
CPC ...
C07K 14/71 (2013.01); A61K 38/1866 (2013.01); C07K 1/113 (2013.01); C07K 1/16 (2013.01); C07K 1/18 (2013.01); C07K 1/22 (2013.01); C07K 1/36 (2013.01); C07K 16/22 (2013.01); C07K 16/283 (2013.01); C12N 5/0018 (2013.01); C12N 5/0031 (2013.01); C12N 15/66 (2013.01); C12P 21/02 (2013.01); C12P 21/06 (2013.01); G01N 30/80 (2013.01); C07K 2317/622 (2013.01); C07K 2319/30 (2013.01); C07K 2319/33 (2013.01); C12N 2800/10 (2013.01); G01N 2030/027 (2013.01);
Abstract
The present disclosure pertains to methods for producing aflibercept from a host cell cultured in a chemically defined medium (CDM) including purification of aflibercept, wherein aflibercept following purification includes aflibercept variants that have at least one oxidized amino acid residue selected from the group consisting of tryptophan, histidine and a combination thereof.